227 related articles for article (PubMed ID: 23116625)
1. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.
von Minckwitz G; Martin M; Wilson G; Alba E; Schmidt M; Biganzoli L; Awada A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):315-31. PubMed ID: 23116625
[TBL] [Abstract][Full Text] [Related]
2. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
5. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
6. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.
Fumoleau P; Cortés-Funes H; Taleb AB; Chan S; Campone M; Pouget JC; Tubiana-Hulin M; Slabber CF; Caroff-Paraïso I; Alberts AS; Ben Ayed F
Am J Clin Oncol; 2009 Aug; 32(4):375-80. PubMed ID: 19487917
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
9. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
10. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.
Biganzoli L; Aapro M; Loibl S; Wildiers H; Brain E
Cancer Treat Rev; 2016 Feb; 43():19-26. PubMed ID: 26827689
[TBL] [Abstract][Full Text] [Related]
11. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
Rivera E
Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD
Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient.
Iorfida M; Mazza M
Future Oncol; 2015; 11(15 Suppl):23-6. PubMed ID: 26235261
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
Xu BH; Jiang ZF; Shen ZZ; Guan ZZ; Chen ZD; Cheng Y; Zheng H; Jiang J; Wang XJ; Tong ZS; Qin SK; Luo Y; Yao M; Wang LW; He J
Chin Med J (Engl); 2012 Mar; 125(5):764-9. PubMed ID: 22490570
[TBL] [Abstract][Full Text] [Related]
15. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
[TBL] [Abstract][Full Text] [Related]
16. Taxanes as a first-line systemic treatment in metastatic breast cancer.
Urquhart LM
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():15-21. PubMed ID: 23360699
[TBL] [Abstract][Full Text] [Related]
17. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
18. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Megerdichian C; Olimpiadi Y; Hurvitz SA
Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy.
Verma S; Clemons M
Oncologist; 2007 Jul; 12(7):785-97. PubMed ID: 17673610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
